Top

Published in:

10-01-2023 | Immunodeficiency | Original Article

Distinct Lymphocyte Immunophenotyping and Quantitative Anti-Interferon Gamma Autoantibodies in Taiwanese HIV-Negative Patients with Non-Tuberculous Mycobacterial Infections

Authors: Wen-I. Lee, Yao-Fan Fang, Jing-Long Huang, Huey-Ling You, Meng-Ying Hsieh, Wan-Ting Huang, Chi-Jou Liang, Chen-Chen Kang, Ting-Shu Wu

Published in: Journal of Clinical Immunology | Issue 4/2023

Abstract

Purpose

The presence of anti-interferon-γ autoantibodies (AutoAbs-IFN-γ) is not rare in patients suffering from persistent non-tuberculous mycobacterial (NTM) infections that are characteristic of adult-onset immunodeficiency syndrome. The immune disturbances in this distinct disorder remain to be elucidated.

Methods

Patients with NTM infections but without effective response over 3 months’ treatment were referred to our institute to quantify their level of AutoAbs-IFN-γ after excluding defective IL12/23-IFN-γ circuit and reactive oxygen species production. The AutoAbs-IFN-γ and percentage of lymphocyte subpopulations most relevant to T and B cell pools were assessed and compared with age-matched healthy controls.

Results

A total of 31 patients were enrolled during the 15-year study period (2008–2022), 20 patients with > 50% suppression of IFN-γ detection at 1:100 serum dilution were classified into the Auto-NTM group. The remaining 11 with negligible suppression were assigned to the No Auto-NTM group. Mycobacterium chimaera-intracellulare group (MAC), M. kansasii, and M. abscessus were the most common pathogens. Pneumonia (19 vs 7), lymphadenitis (11 vs 5), Salmonella sepsis (6 vs 2), osteomyelitis (5 vs 1), and cutaneous herpes zoster (4 vs 4) were the main manifestations in both the Auto-NTM and No Auto-NTM groups who had similar onset-age (55.3 vs 53.6 years; p = 0.73) and follow-up duration (71.9 vs 54.6 months; p = 0.45). The Auto-NTM group had significantly higher transitional (IgM + + CD38 + +), CD19 + CD21-low, and plasmablast (IgM-CD38 + +) in the B cell pool, with higher effector memory (CD4 + /CD8 + CD45RO + CCR7 −), senescent CD8 + CD57 + , and Th17 cells, but lower naïve (CD4 + /CD8 + CD45RO − CCR7 +) and Treg cells in the T cell pool when compared to the No Auto-NTM and healthy groups. NTM patients with/without AutoAbs-IFN-γ had lower Th1-like Tfh (CD4 + CXCR5 + CXCR3 + CCR6 −) cells. All Auto-NTM patients still had non-remitted mycobacterial infections and higher AutoAbs-IFN-γ despite anti-CD20 therapy in 3 patients.

Conclusion

In patients with suspected adult-onset immunodeficiency syndrome, two thirds (20/31) were recognized as having significantly inhibitory AutoAbs-IFN-γ with higher antibody-enhancing transitional, CD19 + CD21-low and plasmablast B cells; as well as higher effector memory, senescent CD8 + CD57 + and Th17 cells, but lower naïve T and Treg cells in contrast to those with negligible AutoAbs-IFN-γ. Such immunophenotyping disturbances might correlate with the presence of AutoAbs-IFN-γ. However, the mutual mechanisms need to be further clarified.

Available only for authorised users

Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367(8):725–34. https://doi.org/10.1056/NEJMoa1111160.CrossRefPubMedPubMedCentral

Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis. 2010;10(12):875–85. https://doi.org/10.1016/S1473-3099(10)70196-1.CrossRefPubMed

Chi CY, Chu CC, Liu JP, et al. Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood. 2013;121(8):1357–66. https://doi.org/10.1182/blood-2012-08-452482.CrossRefPubMed

Shih HP, Ding JY, Yeh CF, Chi CY, Ku CL. Anti-interferon-γ autoantibody-associated immunodeficiency. Curr Opin Immunol. 2021;72:206–14. https://doi.org/10.1016/j.coi.2021.05.007.CrossRefPubMed

Tseng CW, Lai KL, Chen DY, Lin CH, Chen HH. The Incidence and Prevalence of Common Variable Immunodeficiency Disease in Taiwan, A Population-Based Study. Plos One. 2015;10(10):e0140473. https://doi.org/10.1371/journal.pone.0140473.CrossRefPubMedPubMedCentral

Lee WI, Huang JL, Kuo ML, Lin SJ, Chen LC, Chen MT, Jaing TH. Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital. Ann Allergy Asthma Immunol. 2007;99(5):433–42. https://doi.org/10.1016/S1081-1206(10)60569-8.CrossRefPubMed

Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol. 2014;26(6):454–70. https://doi.org/10.1016/j.smim.2014.09.008.CrossRefPubMedPubMedCentral

Rosain J, Kong XF, Martinez-Barricarte R, et al. Mendelian susceptibility to mycobacterial disease: 2014–2018 update. Immunol Cell Biol. 2019;97(4):360–7. https://doi.org/10.1111/imcb.12210.CrossRefPubMed

Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol. 2006;18(6):347–61. https://doi.org/10.1016/j.smim.2006.07.010.CrossRefPubMed

10.

Filipe-Santos O, Bustamante J, Haverkamp MH, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med. 2006;203(7):1745–59. https://doi.org/10.1084/jem.20060085.CrossRefPubMedPubMedCentral

11.

Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001;293(5528):300–3. https://doi.org/10.1126/science.1061154.CrossRefPubMed

12.

Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33(3):388–91. https://doi.org/10.1038/ng1097.CrossRefPubMed

13.

Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol. 2011;12(3):213–21. https://doi.org/10.1038/ni.1992.CrossRefPubMedPubMedCentral

14.

Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med. 2011;365(2):127–38. https://doi.org/10.1056/NEJMoa1100066.CrossRefPubMedPubMedCentral

15.

Lee WI, Huang JL, Wu TS, et al. Patients with inhibitory and neutralizing auto-antibodies to interferon-γ resemble the sporadic adult-onset phenotype of Mendelian Susceptibility to Mycobacterial Disease (MSMD) lacking Bacille Calmette-Guerin (BCG)-induced diseases. Immunobiology. 2013;218(5):762–71. https://doi.org/10.1016/j.imbio.2012.08.281.CrossRefPubMed

16.

Boisson-Dupuis S, Bustamante J. Mycobacterial diseases in patients with inborn errors of immunity. Curr Opin Immunol. 2021;72:262–71. https://doi.org/10.1016/j.coi.2021.07.001.CrossRefPubMedPubMedCentral

17.

Kampitak T, Suwanpimolkul G, Browne S, Suankratay C. Anti-interferon-γ autoantibody and opportunistic infections: case series and review of the literature. Infection. 2011;39(1):65–71. https://doi.org/10.1007/s15010-010-0067-3.CrossRefPubMed

18.

Patel SY, Ding L, Brown MR, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol. 2005;175(7):4769–76. https://doi.org/10.4049/jimmunol.175.7.4769.CrossRefPubMed

19.

Lee WI, Fan WL, Lu CH, et al. A Novel CD3G Mutation in a Taiwanese Patient With Normal T Regulatory Function Presenting With the CVID Phenotype Free of Autoimmunity-Analysis of all Genotypes and Phenotypes. Front Immunol. 2019;10:2833. https://doi.org/10.3389/fimmu.2019.02833.CrossRefPubMedPubMedCentral

20.

Lee WI, Huang JL, Lin TY, et al. Chinese patients with defective IL-12/23-interferon-gamma circuit in Taiwan: partial dominant interferon-gamma receptor 1 mutation presenting as cutaneous granuloma and IL-12 receptor beta1 mutation as pneumatocele. J Clin Immunol. 2009;29(2):238–45. https://doi.org/10.1007/s10875-008-9253-9.CrossRefPubMed

21.

Wu CY, Chen YC, Lee WI, et al. Clinical Features of Female Taiwanese Carriers with X-linked Chronic Granulomatous Disease from 2004 to 2019. J Clin Immunol. 2021;41(6):1303–14. https://doi.org/10.1007/s10875-021-01055-x.CrossRefPubMed

22.

Lange C, Böttger EC, Cambau E, et al. expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary diseases Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022;7(3):e178–90.CrossRef

23.

Zhou Y, Zhang Y, Han J, Yang M, Zhu J, Jin T. Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med. 2020;18(1):131. https://doi.org/10.1186/s12967-020-02289-w.CrossRefPubMedPubMedCentral

24.

Rakhmanov M, Keller B, Gutenberger S, et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci U S A. 2009;106(32):13451–6. https://doi.org/10.1073/pnas.0901984106.CrossRefPubMedPubMedCentral

25.

Pioli PD. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front Immunol. 2019;10:2768. https://doi.org/10.3389/fimmu.2019.02768.CrossRefPubMedPubMedCentral

26.

Yan H, Li B, Su R, Gao C, Li X, Wang C. Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome. Front Immunol. 2022;13:873644. https://doi.org/10.3389/fimmu.2022.873644.CrossRefPubMedPubMedCentral

27.

Xia Y, Fang X, Dai X, et al. Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus. Int Immunopharmacol. 2021;96:107563. https://doi.org/10.1016/j.intimp.2021.107563.CrossRefPubMed

28.

Carvajal Alegria G, Gazeau P, Hillion S, Daïen CI, Cornec DYK. Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases? Clin Rev Allergy Immunol. 2017;53(2):219–36. https://doi.org/10.1007/s12016-017-8608-5.CrossRefPubMed

29.

Thorarinsdottir K, Camponeschi A, Cavallini N, et al. CD21(-/low) B cells in human blood are memory cells. Clin Exp Immunol. 2016;185(2):252–62. https://doi.org/10.1111/cei.12795.CrossRefPubMedPubMedCentral

30.

Zhang J, He T, Xue L, Guo H. Senescent T cells: a potential biomarker and target for cancer therapy. EBioMedicine. 2021;68:103409. https://doi.org/10.1016/j.ebiom.2021.103409.CrossRefPubMedPubMedCentral

31.

Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97. https://doi.org/10.1038/ni.2771.CrossRefPubMed

32.

Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3Kδ and primary immunodeficiencies. Nat Rev Immunol. 2016;16(11):702–14. https://doi.org/10.1038/nri.2016.93.CrossRefPubMedPubMedCentral

33.

Chen YC, Weng SW, Ding JY, et al. Clinicopathological Manifestations and Immune Phenotypes in Adult-Onset Immunodeficiency with Anti-interferon-γ Autoantibodies. J Clin Immunol. 2022;42(3):672–83. https://doi.org/10.1007/s10875-022-01210-y.CrossRefPubMed

34.

Wu UI, Wang JT, Sheng WH, et al. Incorrect diagnoses in patients with neutralizing anti-interferon-gamma-autoantibodies. Clin Microbiol Infect. 2020;26(12):1684.e1-1684.e6. https://doi.org/10.1016/j.cmi.2020.02.030.CrossRefPubMed

35.

Browne SK, Zaman R, Sampaio EP, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012;119(17):3933–9. https://doi.org/10.1182/blood-2011-12-395707.CrossRefPubMedPubMedCentral

36.

Wu UI, Chuang YC, Sheng WH, et al. Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γ autoantibodies in patients with disseminated nontuberculous mycobacterial infection. Clin Microbiol Infect. 2018;24(2):159–65. https://doi.org/10.1016/j.cmi.2017.06.029.CrossRefPubMed

37.

Hong GH, Ortega-Villa AM, Hunsberger S, et al. Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States. Clin Infect Dis. 2020;71(1):53–62. https://doi.org/10.1093/cid/ciz786.CrossRefPubMed

38.

Ochoa S, Ding L, Kreuzburg S, Treat J, Holland SM, Zerbe CS. Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies. Clin Infect Dis. 2021;72(12):2206–8. https://doi.org/10.1093/cid/ciaa1086.CrossRefPubMed

39.

Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597-606.e4. https://doi.org/10.1016/j.jaci.2016.06.021.CrossRefPubMedPubMedCentral

40.

Michalovich D, Nejentsev S. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy. Front Immunol. 2018;9:369. https://doi.org/10.3389/fimmu.2018.00369.CrossRefPubMedPubMedCentral

41.

Ku CL, Lin CH, Chang SW, et al. Anti-IFN-γ autoantibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia. J Allergy Clin Immunol. 2016;137(3):945-8.e8. https://doi.org/10.1016/j.jaci.2015.09.018.CrossRefPubMed

Title: Distinct Lymphocyte Immunophenotyping and Quantitative Anti-Interferon Gamma Autoantibodies in Taiwanese HIV-Negative Patients with Non-Tuberculous Mycobacterial Infections
Authors: Wen-I. Lee
Yao-Fan Fang
Jing-Long Huang
Huey-Ling You
Meng-Ying Hsieh
Wan-Ting Huang
Chi-Jou Liang
Chen-Chen Kang
Ting-Shu Wu
Publication date: 10-01-2023
Publisher: Springer US
Keywords: Immunodeficiency
Interferon
Published in: Journal of Clinical Immunology / Issue 4/2023
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-022-01423-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

STING-Associated Vasculopathy with Onset in infancy (SAVI) Presenting as Massive Intra Alveolar Hemorrhage

“The Regimental Pediatrician”: Forewords and Background

Clinical and Genetic Characteristics of BCG Disease in Chinese Children: a Retrospective Study

The Association of Serum Immunoglobulins with Risk of Cardiovascular Disease and Mortality: the Rotterdam Study

Clinical Non-penetrance Associated with Biallelic Mutations in the RNase H2 Complex

Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials